FORUM Pharmaceuticals announces dosing of the first patient in a clinical trial to evaluate FORUM’s investigational therapy FRM-0334, which is targeting PGRN mutations. For more information, read the presione soltar. To learn more about the clinical trial, visit ensayosclinicos.gov